All Stories

  1. Symptom clusters for revising scale membership in the analysis of prostate cancer patient reported outcome measures: a secondary data analysis of the Medical Research Council RT01 trial (ISCRTN47772397)

    Article • Quality of Life Research, March 2017, Springer Science + Business Media

    Mr Matthew R Sydes

  2. National, centralised hospital datasets can inform clinical trial outcomes in prostate cancer: A pilot study in the STAMPEDE trial.

    Article • Journal of Clinical Oncology, February 2017, American Society of Clinical Oncology (ASCO)

    Mr Matthew R Sydes

  3. Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform

    Article • European Urology, December 2016, Elsevier

    Mr Matthew R Sydes

  4. How do you design randomised trials for smaller populations? A framework

    Article • BMC Medicine, November 2016, Springer Science + Business Media

    Mr Matthew R Sydes

  5. Response to ‘High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice’, by Tanguay et al.

    Article • Clinical Oncology, October 2016, Elsevier

    Mr Matthew R Sydes

  6. Reply to Che-Kai Tsao, Matthew D. Galsky, and William K. Oh's Platinum Opinion. Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer: Urgent Need To Minimize The Risk Of Neutropenic Fever. Eur Urol 2016;70:707–708

    Article • European Urology, October 2016, Elsevier

    Mr Matthew R Sydes

  7. Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer

    Article • European Urology Focus, August 2016, Elsevier

    Mrs Annabelle South, Mr Matthew R Sydes

  8. STAMPEDE trial and patients with non-metastatic prostate cancer – Authors' reply

    Article • The Lancet, July 2016, Elsevier

    Mr Matthew R Sydes

  9. Data sharing and the evolving role of statisticians

    Article • BMC Medical Research Methodology, July 2016, Springer Science + Business Media

    Mr Matthew R Sydes

  10. What are the roles and valued attributes of a Trial Steering Committee? Ethnographic study of eight clinical trials facing challenges

    Article • Trials, July 2016, Springer Science + Business Media

    Mr Matthew R Sydes, Dr Gillian W Shorter

  11. Best practice for analysis of shared clinical trial data

    Article • BMC Medical Research Methodology, July 2016, Springer Science + Business Media

    Mr Matthew R Sydes, Catrin Tudur Smith

  12. Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer

    Article • JAMA Oncology, March 2016, American Medical Association (AMA)

    Mr Matthew R Sydes

  13. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    Article • The Lancet, March 2016, Elsevier

    Mr Matthew R Sydes

  14. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

    Article • The Lancet Oncology, February 2016, Elsevier

    Mr Matthew R Sydes

  15. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa–pT1 Urothelial Carcin...

    Article • European Urology, February 2016, Elsevier

    Mr Matthew R Sydes

  16. UK publicly funded Clinical Trials Units supported a controlled access approach to share individual participant data but highlighted concerns

    Article • Journal of Clinical Epidemiology, February 2016, Elsevier

    Mr Matthew R Sydes, Catrin Tudur Smith

  17. Will chemotherapy change the management of prostate cancer?

    Article • BJU International, January 2016, Wiley

    Mr Matthew R Sydes

  18. Systemic therapy for vulval Erosive Lichen Planus (the ‘hELP’ trial): study protocol for a randomised controlled trial

    Article • Trials, January 2016, Springer Science + Business Media

    Mr Matthew R Sydes

  19. Trial Steering Committees in randomised controlled trials: A survey of registered clinical trials units to establish current practice and experiences

    Article • Clinical Trials, December 2015, SAGE Publications

    Mr Matthew R Sydes

  20. Exploring the role and function of trial steering committees: results of an expert panel meeting

    Article • Trials, December 2015, Springer Science + Business Media

    Mr Matthew R Sydes

  21. How should individual participant data (IPD) from publicly funded clinical trials be shared?

    Article • BMC Medicine, December 2015, Springer Science + Business Media

    Mr Matthew R Sydes

  22. A framework for the design and analysis of phase III randomised trials in uncommon diseases

    Article • Trials, November 2015, Springer Science + Business Media

    Mr Matthew R Sydes

  23. Reporting remit and function of trial steering committees in randomised controlled trials: review of published literature

    Article • Trials, November 2015, Springer Science + Business Media

    Mr Matthew R Sydes

  24. Exploring the role and functionality of trial steering committees

    Article • Trials, November 2015, Springer Science + Business Media

    Mr Matthew R Sydes

  25. The value of evidence synthesis in randomised controlled trial (RCT) design, conduct and analysis: MRC clinical trials unit (CTU) at UCL experience

    Article • Trials, November 2015, Springer Science + Business Media

    Mr Matthew R Sydes

  26. Enhancing public involvement in trial oversight committees through qualitative research with eight trials facing challenges

    Article • Trials, November 2015, Springer Science + Business Media

    Mr Matthew R Sydes, Dr Gillian W Shorter

  27. Good practice principles for sharing individual participant data from publicly funded clinical trials

    Article • Trials, November 2015, Springer Science + Business Media

    Mr Matthew R Sydes

  28. The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP)

    Article • JNCI Journal of the National Cancer Institute, September 2015, Oxford University Press (OUP)

    Mr Matthew R Sydes

  29. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Resp...

    Article • Journal of Clinical Oncology, July 2015, American Society of Clinical Oncology (ASCO)

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  30. Comments on ‘A modest proposal for dropping poor arms in clinical trials’ by Proschan and Dodd

    Article • Statistics in Medicine, July 2015, Wiley

    Mr Matthew R Sydes

  31. Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer

    Article • Journal of Clinical Oncology, July 2015, American Society of Clinical Oncology (ASCO)

    Mr Matthew R Sydes

  32. Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial

    Article • Journal of Clinical Oncology, July 2015, American Society of Clinical Oncology (ASCO)

    Mr Matthew R Sydes

  33. Making randomised trials more efficient: report of the first meeting to discuss the Trial Forge platform

    Article • Trials, June 2015, Springer Science + Business Media

    Mr Matthew R Sydes

  34. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

    Article • European Urology, June 2015, Elsevier

    Mr Matthew R Sydes

  35. Sharing data from clinical trials: the rationale for a controlled access approach

    Article • Trials, March 2015, Springer Science + Business Media

    Mrs Annabelle South, Mr Matthew R Sydes

  36. Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative

    Article • European Journal of Cancer, February 2015, Elsevier

    Mr Matthew R Sydes

  37. Outcomes and endpoints in cancer trials: bridging the divide

    Article • The Lancet Oncology, January 2015, Elsevier

    Mr Matthew R Sydes

  38. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment

    Article • Annals of Oncology, November 2014, Oxford University Press (OUP)

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  39. Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial

    Article • European Urology, November 2014, Elsevier

    Mr Matthew R Sydes

  40. More multiarm randomised trials of superiority are needed

    Article • The Lancet, July 2014, Elsevier

    Mr Matthew R Sydes

  41. A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1

    Article • Nature Genetics, June 2014, Nature

    Mr Matthew R Sydes

  42. No socioeconomic inequalities in ovarian cancer survival within two randomised clinical trials

    Article • British Journal of Cancer, June 2014, Nature

    Mr Matthew R Sydes

  43. Postoperative Radiotherapy After Radical Prostatectomy: Let's Work Together to Tackle the Known Unknowns

    Article • European Urology, June 2014, Elsevier

    Mr Matthew R Sydes

  44. A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity

    Article • Radiotherapy and Oncology, May 2014, Elsevier

    Mr Matthew R Sydes

  45. Can we deliver randomized trials of focal therapy in prostate cancer?

    Article • Nature Reviews Clinical Oncology, April 2014, Nature

    Mr Matthew R Sydes

  46. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial

    Article • The Lancet Oncology, April 2014, Elsevier

    Mr Matthew R Sydes

  47. MP53-20 THE PREDICTIVE VALUE OF 2-YEAR POST-TREATMENT BIOPSY AFTER PROSTATE CANCER CONFORMAL RADIOTHERAPY FOR FUTURE OVERALL SURVIVAL AND BIOCHEMICAL FAILURE. THE RESULTS OF THE UK MRC RT01 TRIAL.

    Article • The Journal of Urology, April 2014, Elsevier

    Mr Matthew R Sydes, Mr Antoine Kass-iliyya

  48. Workshop report on the 2nd Joint ENCCA/EuroSARC European bone sarcoma network meeting: integration of clinical trials with tumour biology

    Article • Clinical Sarcoma Research, January 2014, Springer Science + Business Media

    Mr Matthew R Sydes

  49. Re: Sanoj Punnen, Matthew R. Cooperberg, Anthony V. D’Amico, et al. Management of Biochemical Recurrence After Primary Treatment of Prostate Cancer: A Systematic Review of the Literature. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.05.025

    Article • European Urology, November 2013, Elsevier

    Mr Matthew R Sydes

  50. Reply to Chris Parker, Matthew R. Sydes and Howard Kynaston's Letter to the Editor re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: ...

    Article • European Urology, November 2013, Elsevier

    Mr Matthew R Sydes

  51. Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis

    Article • Journal of Clinical Oncology, June 2013, American Society of Clinical Oncology (ASCO)

    Mr Matthew R Sydes

  52. Prostate Radiotherapy for Men with Metastatic Disease: A New Comparison in the STAMPEDE Trial

    Article • Clinical Oncology, May 2013, Elsevier

    Mr Matthew R Sydes

  53. Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial

    Article • BJU International, April 2013, Wiley

    Mr Matthew R Sydes

  54. Response to: Practical methods for incorporating summary time-to-event data into meta-analysis

    Article • Trials, January 2013, Springer Science + Business Media

    Mr Matthew R Sydes

  55. The need for a cultural shift from two-arm to multi-arm RCTS

    Article • Trials, January 2013, Springer Science + Business Media

    Mr Matthew R Sydes

  56. An ethnographic study of group decision making to understand and improve how trial steering committees contribute to trial conduct

    Article • Trials, January 2013, Springer Science + Business Media

    Mr Matthew R Sydes

  57. A double-blind placebo-controlled randomised trial of oral sodium clodronate for metastatic prostate adenocarcinoma

    Article • December 2012, Springer Science + Business Media

    Mr Matthew R Sydes

  58. High dose therapy in localised cancer of the prostate using conformal radiotherapy techniques

    Article • December 2012, Springer Science + Business Media

    Mr Matthew R Sydes

  59. A double-blind placebo controlled randomised trial of oral sodium clodronate for locally advanced prostatic adenocarcinoma

    Article • December 2012, Springer Science + Business Media

    Mr Matthew R Sydes

  60. Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative Radiation Therapy for Pathologically Advanced Prostate Cancer After Radical Prostatectomy. Eur Urol 2012;61:443–51

    Article • European Urology, December 2012, Elsevier

    Mr Matthew R Sydes

  61. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial

    Article • Trials, September 2012, Springer Science + Business Media

    Mr Matthew R Sydes

  62. The dose–response of the anal sphincter region – An analysis of data from the MRC RT01 trial

    Article • Radiotherapy and Oncology, June 2012, Elsevier

    Mr Matthew R Sydes

  63. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial

    Article • The Lancet Oncology, May 2012, Elsevier

    Mr Matthew R Sydes

  64. Socio-economic inequalities in testicular cancer survival within two clinical studies

    Article • Cancer Epidemiology, April 2012, Elsevier

    Mr Matthew R Sydes

  65. Parameters for the Lyman Kutcher Burman (LKB) model of Normal Tissue Complication Probability (NTCP) for specific rectal complications observed in clinical practise

    Article • Radiotherapy and Oncology, March 2012, Elsevier

    Mr Matthew R Sydes

  66. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup

    Article • European Journal of Cancer, March 2012, Elsevier

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  67. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study

    Article • The Lancet Oncology, January 2012, Elsevier

    Mr Matthew R Sydes

  68. Emotion Detection in Suicide Notes using Maximum Entropy Classification

    Article • Biomedical Informatics Insights, January 2012, Libertas Academica, Ltd.

    Mr Matthew R Sydes

  69. Adjuvant Radiotherapy After Prostatectomy: Does Waiting for a Detectable Prostate-Specific Antigen Level Make Sense?: In Regard to King CR (Int J Radiat Oncol Biol Phys 2011;80:1–3)

    Article • International Journal of Radiation Oncology*Biology*Physics, December 2011, Elsevier

    Mr Matthew R Sydes

  70. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

    Article • The Lancet, December 2011, Elsevier

    Mr Matthew R Sydes

  71. The Impact of Clinical Factors on the Development of Late Radiation Toxicity: Results from the Medical Research Council RT01 Trial (ISRCTN47772397)

    Article • Clinical Oncology, November 2011, Elsevier

    Mr Matthew R Sydes

  72. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials

    Article • Annals of Oncology, October 2011, Oxford University Press (OUP)

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  73. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015)

    Article • Radiotherapy and Oncology, July 2011, Elsevier

    Mr Matthew R Sydes

  74. Reflections on attempted Anglo-Japanese collaboration on STAMPEDE: A randomized controlled trial for men with prostate cancer

    Article • International Journal of Urology, May 2011, Wiley

    Mr Matthew R Sydes

  75. Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials

    Article • European Journal of Cancer, April 2011, Elsevier

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  76. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

    Article • The Lancet, October 2010, Elsevier

    Mr Matthew R Sydes

  77. Expression of Bcl-2, p53, and MDM2 in Localized Prostate Cancer With Respect to the Outcome of Radical Radiotherapy Dose Escalation

    Article • International Journal of Radiation Oncology*Biology*Physics, September 2010, Elsevier

    Mr Matthew R Sydes

  78. When should radiotherapy be used after radical prostatectomy? The RADICALS-RT Trial

    Article • British Journal of Medical and Surgical Urology, September 2010, SAGE Publications

    Mr Matthew R Sydes

  79. PROSTATE RADIOTHERAPY AFTER RADICAL PROSTATECTOMY: SOONER OR LATER?

    Article • BJU International, August 2010, Wiley

    Mr Matthew R Sydes

  80. Consolidation Radiotherapy in Patients With Advanced Hodgkin's Lymphoma: Survival Data From the UKLG LY09 Randomized Controlled Trial (ISRCTN97144519)

    Article • Journal of Clinical Oncology, July 2010, American Society of Clinical Oncology (ASCO)

    Mr Matthew R Sydes

  81. Late Gastrointestinal Toxicity After Dose-Escalated Conformal Radiotherapy for Early Prostate Cancer: Results From the UK Medical Research Council RT01 Trial (ISRCTN47772397)

    Article • International Journal of Radiation Oncology*Biology*Physics, July 2010, Elsevier

    Mr Matthew R Sydes

  82. Potential pitfalls in the design and reporting of clinical trials

    Article • The Lancet Oncology, July 2010, Elsevier

    Mr Matthew R Sydes

  83. Dose–Volume Constraints to Reduce Rectal Side Effects From Prostate Radiotherapy: Evidence From MRC RT01 Trial ISRCTN 47772397

    Article • International Journal of Radiation Oncology*Biology*Physics, March 2010, Elsevier

    Mr Matthew R Sydes

  84. A comparison of dose–volume constraints derived using peak and longitudinal definitions of late rectal toxicity

    Article • Radiotherapy and Oncology, February 2010, Elsevier

    Mr Matthew R Sydes

  85. Early Salvage Radiotherapy After Radical Prostatectomy

    Article • Journal of Clinical Oncology, January 2010, American Society of Clinical Oncology (ASCO)

    Mr Matthew R Sydes

  86. Applying for ethical approval for research in the United Kingdom

    Article • BMJ, October 2009, BMJ

    Mr Matthew R Sydes

  87. Assessing correlations between the spatial distribution of the dose to the rectal wall and late rectal toxicity after prostate radiotherapy: an analysis of data from the MRC RT01 trial (ISRCTN 47772397)

    Article • Physics in Medicine and Biology, October 2009, Institute of Physics Publishing

    Mr Matthew R Sydes

  88. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

    Article • The Lancet Oncology, September 2009, Elsevier

    Mr Matthew R Sydes

  89. Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519)

    Article • Annals of Oncology, August 2009, Oxford University Press (OUP)

    Mr Matthew R Sydes

  90. COMPARISON OF PEAK VS TIME-DEPENDENT LATE RECTAL TOXICITY IN PROSTATE RADIOTHERAPY

    Article • Radiotherapy and Oncology, August 2009, Elsevier

    Mr Matthew R Sydes

  91. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial

    Article • Trials, June 2009, Springer Science + Business Media

    Mr Matthew R Sydes

  92. Re: Ofer Yossepowitch, Anders Bjartell, James A. Eastham, et al. Positive Surgical Margins in Radical Prostatectomy: Outlining the Problem and Its Long-Term Consequences. Eur Urol 2009;55:87–99

    Article • European Urology, June 2009, Elsevier

    Mr Matthew R Sydes

  93. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial

    Article • BJU International, February 2009, Wiley

    Mr Matthew R Sydes

  94. Re: Ute Ganswindt, Arnulf Stenzl, Michael Bamberg and Claus Belka. Adjuvant Radiotherapy for Patients with Locally Advanced Prostate Cancer—A New Standard? Eur Urol 2008;54:528–42

    Article • European Urology, February 2009, Elsevier

    Mr Matthew R Sydes

  95. Reply to Chris Parker and Matthew R. Sydes’ Letter to the Editor re: Ute Ganswindt, Arnulf Stenzl, Michael Bamberg and Claus Belka. Adjuvant Radiotherapy for Patients with Locally Advanced Prostate Cancer—A New Standard? Eur Urol 2008;54:528–42

    Article • European Urology, February 2009, Elsevier

    Mr Matthew R Sydes

  96. International Collaboration is Feasible in Trials for Rare Conditions: The EURAMOS Experience

    Article • January 2009, Springer Science + Business Media

    Mr Matthew R Sydes

  97. Adjuvant Radiotherapy After Surgery for Prostate Cancer

    Article • JAMA, November 2008, American Medical Association (AMA)

    Mr Matthew R Sydes

  98. Prostate cancer staging tables—A predictive model for the UK

    Article • British Journal of Medical and Surgical Urology, November 2008, SAGE Publications

    Mr Matthew R Sydes

  99. No socioeconomic inequalities in colorectal cancer survival within a randomised clinical trial

    Article • British Journal of Cancer, October 2008, Nature

    Mr Matthew R Sydes

  100. Accuracy and Reproducibility of Conformal Radiotherapy using Data from a Randomised Controlled Trial of Conformal Radiotherapy in Prostate Cancer (MRC RT01, ISRCTN47772397)

    Article • Clinical Oncology, October 2008, Elsevier

    Mr Matthew R Sydes

  101. STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer — A Multi-Arm Multi-Stage Randomised Controlled Trial

    Article • Clinical Oncology, October 2008, Elsevier

    Mr Matthew R Sydes

  102. Speeding up the Evaluation of New Agents in Cancer

    Article • JNCI Journal of the National Cancer Institute, August 2008, Oxford University Press (OUP)

    Mr Matthew R Sydes

  103. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study

    Article • The Lancet Oncology, April 2008, Elsevier

    Mr Matthew R Sydes

  104. Resolving the Optimal Timing of Radiotherapy After Radical Prostatectomy: The Need for Further Research

    Article • Journal of Clinical Oncology, April 2008, American Society of Clinical Oncology (ASCO)

    Mr Matthew R Sydes

  105. Interim monitoring of efficacy data is important and appropriate

    Article • Journal of Clinical Epidemiology, March 2008, Elsevier

    Mr Matthew R Sydes

  106. Parenteral oestrogen in the treatment of prostate cancer: a systematic review

    Article • British Journal of Cancer, February 2008, Nature

    Dr Gill Norman, Mr Matthew R Sydes

  107. Using Implicit Information to Identify Smoking Status in Smoke-blind Medical Discharge Summaries

    Article • Journal of the American Medical Informatics Association, January 2008, Oxford University Press (OUP)

    Mr Matthew R Sydes

  108. Practical methods for incorporating summary time-to-event data into meta-analysis

    Article • Trials, June 2007, Springer Science + Business Media

    Mr Matthew R Sydes

  109. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

    Article • The Lancet Oncology, June 2007, Elsevier

    Mr Matthew R Sydes

  110. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy

    Article • BJU International, June 2007, Wiley

    Mr Matthew R Sydes

  111. Oral Sodium Clodronate for Nonmetastatic Prostate Cancer--Results of a Randomized Double-Blind Placebo-Controlled Trial: Medical Research Council PR04 (ISRCTN61384873)

    Article • JNCI Journal of the National Cancer Institute, May 2007, Oxford University Press (OUP)

    Mr Matthew R Sydes

  112. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery)

    Article • Clinical Oncology, April 2007, Elsevier

    Mr Matthew R Sydes

  113. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397)

    Article • Radiotherapy and Oncology, April 2007, Elsevier

    Mr Matthew R Sydes

  114. The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397)

    Article • BJU International, February 2007, Wiley

    Mr Matthew R Sydes

  115. Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup

    Article • JNCI Journal of the National Cancer Institute, January 2007, Oxford University Press (OUP)

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  116. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: Using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397)

    Article • Radiotherapy and Oncology, September 2006, Elsevier

    Mr Matthew R Sydes

  117. Comparison of Outcomes in Studies of Advanced Hodgkin's Lymphoma

    Article • Journal of Clinical Oncology, July 2006, American Society of Clinical Oncology (ASCO)

    Mr Matthew R Sydes

  118. Clinico-histologic parameters of osteosarcoma patients with late relapse

    Article • European Journal of Cancer, March 2006, Elsevier

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  119. Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)

    Article • Journal of Clinical Oncology, December 2005, American Society of Clinical Oncology (ASCO)

    Mr Matthew R Sydes

  120. Is Duplex Surveillance of Value After Leg Vein Bypass Grafting?: Principal Results of the Vein Graft Surveillance Randomised Trial (VGST)

    Article • Circulation, September 2005, Wolters Kluwer Health

    Mr Matthew R Sydes

  121. Defining the Need for Local Therapy in Locally Advanced Prostate Cancer: An Appraisal of the MRC PR07 Study

    Article • Clinical Oncology, June 2005, Elsevier

    Mr Matthew R Sydes

  122. Perioperative β-blockade (Pobble) for patients undergoing infrarenal vascular surgery: Results of a randomized double-blind controlled trial

    Article • Journal of Vascular Surgery, April 2005, Elsevier

    Mr Matthew R Sydes

  123. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer

    Article • Radiotherapy and Oncology, August 2004, Elsevier

    Mr Matthew R Sydes

  124. Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study

    Article • Clinical Trials, February 2004, SAGE Publications

    Mr Matthew R Sydes

  125. Systematic qualitative review of the literature on data monitoring committees for randomized controlled trials

    Article • Clinical Trials, February 2004, SAGE Publications

    Mr Matthew R Sydes

  126. High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin’s Lymphoma: Results From the Randomized European CUP Trial

    Article • Journal of Clinical Oncology, November 2003, American Society of Clinical Oncology (ASCO)

    Mr Matthew R Sydes

  127. A Double-Blind, Placebo-Controlled, Randomized Trial of Oral Sodium Clodronate for Metastatic Prostate Cancer (MRC PR05 Trial)

    Article • JNCI Journal of the National Cancer Institute, September 2003, Oxford University Press (OUP)

    Mr Matthew R Sydes

  128. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study

    Article • Annals of Oncology, August 2002, Oxford University Press (OUP)

    Mr Matthew R Sydes

  129. Article • Annals of Oncology, January 2000, Oxford University Press (OUP)

    Mr Matthew R Sydes

  130. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial

    Article • British Journal of Cancer, March 1999, Nature

    Mr Matthew R Sydes

  131. Are Structured Abstracts Easier to Read Than Traditional Ones?. Les resumes structures sont-ils plus faciles a lire que les resumes traditionnels?

    Article • Journal of Research in Reading, June 1997, Wiley

    Mr Matthew R Sydes

  132. A Thorn in the Flesch: Observations on the Unreliability of Computer-Based Readability Formulae

    Article • British Journal of Educational Technology, April 1997, Wiley

    Mr Matthew R Sydes

  133. Obtaining information accurately and quickly: are structured abstracts more efficient?

    Article • Journal of Information Science, October 1996, SAGE Publications

    Mr Matthew R Sydes

  134. Which layout do you prefer? An analysis of readers' preferences for different typographic layouts of structured abstracts

    Article • Journal of Information Science, February 1996, SAGE Publications

    Mr Matthew R Sydes